Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.
Contact us to learn how Vital Transformation can help your organisation.
LATEST RESEARCH
LATEST COMMUNICATIONS

Our Communication Services
In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on the Inflation Reduction Act (IRA) and its ripple effects across drug development, Medicare, and patient access. Over the past year, the biopharma industry and the broader healthcare system have undergone a period of rapid change as new rules surrounding drug pricing reshape how therapies are developed, financed, and delivered. In a landscape where policies are still being interpreted and adjusted, and where the long-term impact on innovation and access is far from certain, this episode serves as a year-end guide to what has changed and how to think about the road ahead.
Find all our communication projects on Better Science, Better Health
MORE RESEARCH
Whole-Body Magnetic Resonance Angiography (WBMRA) as a tool for driving efficiency in the cost and treatment of Claudication Comorbities
12th September, 2013
Abstract
Whole-Body Magnetic Resonance Angiography (WBMRA) consists of a contrast-enhanced Magnetic Resonance Angiogram (MRA) scan of the entire body in a single step. In the diagnosis of cardiovascular co-morbidities in Peripheral Arterial Disease (PAD), the utilization of WBMRA can streamline the diagnostic process by minimizing the usage of MRA, CT, and Angiograms. In this work, the potential cost savings to the hospital by using WBMRA in PAD are modeled based on collected data that accounts for all interventions in the radiological department of a set of 50 patients with Claudication in the period 2008–2012 at Ninewells Hospital (NHS Tayside).
Innovation Requires a New Regulatory Framework to Improve Research and Development of New Medical Therapies
20th June, 2013
By Duane Schulthess
For targeted medicines, the current processes of regulatory evaluation, decision frameworks and delivery systems are limiting the implementation of new, better therapies. A healthcare ecosystem designed to enable innovation must also support R&D that is cost effective for all stakeholders and make-good on the promise that innovative medicines can effectively deliver the right prevention and treatment to the right patient at the right time.
Acute coronary syndrome: What is the cost-effectiveness of prevention, point-of-care technology and telemonitoring?
September, 2012
Abstract
This study is a cost-analysis that calculates the impact of three interventions for patients identified as ‘at risk’ for Acute Coronary Syndrome – a cardio-vascular exercise programme, point-of-care digital diagnostics, and telemonitoring adherence tools. The results demonstrate that the largest impact is measured when all three interventions are utilized simultaneously producing a cumulative savings of €4424 and 0.126 QALY per patient. We also find a significant decrease in Emergency Room visits by 15% and changes in rates of utilization of Catharization (−59%), Angioplasty (−59%), Bypass (−17%), Medication (−14%) and Rehabilitation (−13%).
VITAL HEALTH PODCASTS
Our podcast series is also available via your favourite channels!
![]() |
![]() |
|---|---|
![]() |
![]() |
NEWSLETTER
Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…
VT on X
Claims that the IRA wouldn’t affect innovation overlooked how early-stage investors really make decisions. Our research shows the pipeline for senior-focused therapies is already narrowing.
— VitalTransformation (@VitalTransform) April 18, 2025
Read the full breakdown: https://t.co/4EzJGdMcU4@weworkforhealth #IRA #DrugPricing
The IRA’s 9-year cap for small molecules and 13-year cap for biologics rerouted investment away from the pills seniors rely on. We sat down with @steveusdin1 to unpack how this shift skews R&D incentives and future therapies.
— VitalTransformation (@VitalTransform) April 27, 2025
Listen here: https://t.co/FCjKFdIhsU@weworkforhealth pic.twitter.com/phoDI4ZrhK
Our clients include many of the world’s leading health care organisations.







































